Treanda

Type: Product
Name: Treanda
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

Andre Goy, MDLymphoma expert Andre Goy, MD, discussed the emerging landscape of mantle cell lymphoma (MCL) therapy at the 18th Annual International Congress on Hematologic Malignancies. Several novel agents are being tested in clinical trials for MCL. ... [Published OncLive - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments

/PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists'' prescribing decisions for relapsed/refractory ... [Published Asian Hospital & Healthcare Management - Apr 15 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

Adding Idelalisib to Rituximab Improved Survival in Patients With Relapsed CLL

By Charlotte BathApril 15, 2014, Volume 5, Issue 6Receiving rituximab (Rituxan) with idelalisib, rather than rituximab with placebo, “significantly improved progression-free survival, response rate, and overall survival” among patients with relapsed chronic ... [Published The ASCO Post - Apr 12 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Bendamustine plus rituximab noninferior to standard therapy in NHL, mantle cell lymphomas

In patients with slowly progressing non-Hodgkin’s lymphoma or mantle cell lymphoma, a regimen of bendamustine and rituximab is noninferior to standard treatment in terms of response rate and safety profile, according to findings from the BRIGHT study ... [Published Orthopedics Today - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments

/PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists' prescribing decisions for relapsed/refractory ... [Published TickerTech.com - Apr 10 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Cephalaon sues DRL over leukemia drug

Biopharmaceuticals company Cephalon, Teva’s subsidiary, has sued Dr Reddy’s Laboratories for infringing their patent for leukemia drug ‘Treanda,’ as the Indian company hoped to make a copycat version of this drug intending to sell it a price lower than ... [Published Financial Chronicle - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Emergent BioSolutions Is Building An Enviable BioDefense Portfolio

Summary- 3-year strategic growth plan is proceeding ahead of schedule and will drive momentum into 2015. - Operational launch at a new manufacturing facility will nearly triple production of BioThrax, the company’s largest revenue generator and the only ... [Published Seeking Alpha - Mar 17 2014]
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Cephalon files suit against Actavis on generic Treanda

Actavis plc, a global integrated specialty pharmaceutical company, has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market bendamustine hydrochloride for injection, 25 mg/vial and ... [Published PharmaBiz - Feb 06 2014]
First reported Feb 04 2014 - Updated Feb 04 2014 - 1 reports

Actavis Confirms Generic Treanda® Patent Challenge

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, ... [Published PR Newswire: Policy & Public Interest - Feb 04 2014]
First reported Dec 31 2013 - Updated Dec 31 2013 - 1 reports

Cephalon files patent infringement suit against Glenmark's bendamustine hydrochloride

Glenmark Pharmaceuticals Limited and Glenmark Generics Inc., USA (Glenmark) recently confirmed that Cephalon Inc. has filed a patent infringement suit on December 26, 2013 in the US District Court for the District of Delaware seeking to prevent Glenmark ... [Published PharmaBiz - Dec 31 2013]

Quotes

...algorithm; therapies such as FCR and BR have proven to be efficacious in this setting, but an improved overall survival remains an unmet need. "Ibrutinib monotherapy is now FDA-approved for R/R CLL, and the drug continues to generate tremendous interest as a result of its proven efficacy; the ibrutinib/BR combination has the potential to offer overall survival and disease progression improvements in the relapsed/refractory CLL/SLL setting."
...Anand Deshpande, Chairman, Managing Director and CEO of Persistent Systems. "The creation of Accelerite brings the organizational alignment to achieve global leadership for these products."
"When we put out the three year plan, the grounding for that trajectory was really built around our historic growth, both on revenue and net income over the last 10 years. We are now working on an updated plan going beyond that '15 period. So I think as we develop that plan and we identify what we believe are reasonable targets for the organization going forward, we'll be in a position to update it. But I wouldn't expect anything in 2014."

More Content

All (12) | News (11) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Treatment Landscape for Mantle Cell Lymphoma Co... [Published OncLive - Apr 16 2014]
Emerging Therapies in Development for Relapsed/... [Published Asian Hospital & Healthcare Management - Apr 15 2014]
Adding Idelalisib to Rituximab Improved Surviva... [Published The ASCO Post - Apr 12 2014]
Bendamustine plus rituximab noninferior to stan... [Published Orthopedics Today - Apr 11 2014]
Emerging Therapies in Development for Relapsed/... [Published TickerTech.com - Apr 10 2014]
Sensex, Nifty slide to 2-week closing low [Published Business Standard India - Mar 20 2014]
Cephalaon sues DRL over leukemia drug [Published Financial Chronicle - Mar 18 2014]
Emergent BioSolutions Is Building An Enviable B... [Published Seeking Alpha - Mar 17 2014]
Cephalon files suit against Actavis on generic ... [Published PharmaBiz - Feb 06 2014]
Actavis Confirms Generic Treanda® Patent Challenge [Published PR Newswire: Policy & Public Interest - Feb 04 2014]
Cephalon files patent infringement suit against... [Published PharmaBiz - Dec 31 2013]
New Products up 48%, Lundbeck raises expectatio... [Published GlobeNewswire - Aug 07 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Actavis Confirms Generic Treanda® Patent Challenge [Published PR Newswire: Policy & Public Interest - Feb 04 2014]
DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.